CoreCap Advisors’s Neurogene NGNE Stock Holding History

CoreCap Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11	Closed	-$129	–	3069
2025 Q1	$129	Hold	11	–	–	﹤0.01%	3041
2024 Q4	$251	Buy	+11	New	+$409	﹤0.01%	2690

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

CoreCap Advisors's NGNE Position: Q2 2025 in Review

CoreCap Advisors sold out of Neurogene (NGNE) in Q2 2025, closing a stake of 11 shares — an estimated $129 sold.

CoreCap Advisors first reported a position in NGNE in Q4 2024 and held it in 2 quarters. The position peaked at $251 in Q4 2024. 82 funds tracked by Wall St. Rank hold NGNE as of Q2 2025.

CoreCap Advisors reported no remaining Neurogene position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 11 Neurogene shares in Q2 2025, an estimated $129.
CoreCap Advisors first reported a position in Neurogene in Q4 2024 and held it in 2 quarters.
CoreCap Advisors's Neurogene position peaked at $251 in Q4 2024.
82 funds tracked by Wall St. Rank held Neurogene as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.